- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: ucart19.
Displaying page 1 of 1.
EudraCT Number: 2016-000297-38 | Sponsor Protocol Number: CL1-68587-003 | Start Date*: 2016-06-22 | ||||||||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | ||||||||||||||||||
Full Title: Long-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor) | ||||||||||||||||||
Medical condition: Advanced lymphoid malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) FR (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004293-15 | Sponsor Protocol Number: UCART19_02(CL1-68587-001) | Start Date*: 2016-05-24 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | |||||||||||||
Full Title: A phase 1, open label, non-comparative, study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory B-cell acute lymphobla... | |||||||||||||
Medical condition: Paediatric relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000296-24 | Sponsor Protocol Number: CL1-68587-002 | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | |||||||||||||
Full Title: Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen recepto... | |||||||||||||
Medical condition: Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.